Dalpiciclib plus hormone therapy for early-stage breast cancer before surgery
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new combination of oral hormone therapy (an aromatase inhibitor) plus a CDK4/6 inhibitor (dalpiciclib) for women with early-stage but locally advanced (Stage II–III) hormone receptor-positive, HER2-negative breast cancer. The goal is to shrink the tumor before surgery, potentially improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman who is either postmenopausal or still having periods (but premenopausal women can also join).
- Your breast cancer is hormone receptor-positive (HR+) and HER2-negative (HER2-).
- Your cancer is Stage II or III (not Stage IV or early Stage I).
- You have not had any previous cancer treatment (like chemo, radiation, or hormone therapy) for this breast cancer.
- You can swallow pills and have good organ function (kidney, liver, bone marrow).
- You are not pregnant, breastfeeding, and are willing to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
This trial tests a combination of three drugs (dalpiciclib, letrozole, and anlotinib) given before surgery to postmenopausal women with stage II or III HR+/HER2- breast cancer. The goal is to see if this neoadjuvant treatment shrinks tumors and improves outcomes.
This trial tests whether a combination of two pills (dalpiciclib and letrozole) can help maintain control of hormone-receptor-positive, HER2-negative breast cancer after initial chemotherapy. It is for people whose cancer has spread or returned and who have not been on an oral CDK4/6 inhibitor before.
This trial is testing a combination of three drugs (dalpiciclib, entinostat, and letrozole) for women with early-stage, hormone-receptor-positive, HER2-negative breast cancer. It aims to see if adding these medications before surgery can help shrink the tumor.
This study tests whether combining two drugs (dalpiciclib and SHR-A1811) before surgery can shrink early-stage breast cancers that are hormone-sensitive and HER2-low. The goal is to see if this approach improves outcomes for patients with intermediate-to-high risk disease.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.